Immunomodulating cyclotides for the treatment of autoimmune diseases

Cyxone is focused on developing innovative therapies aimed at treating autoimmune diseases, specifically rheumatoid arthritis and multiple sclerosis. Their lead drug candidate for rheumatoid arthritis, rabeximod, is characterized by a unique mechanism of action that allows for oral administration, which enhances patient convenience. Additionally, rabeximod is noted for its favorable tolerability profile, making it a potentially safer option for patients. For multiple sclerosis, Cyxone is advancing T20K, a therapy designed to halt or slow the disease's progression, thereby aiming to improve the quality of life for those affected by this debilitating condition.

The company's mission centers on providing more effective and safer treatment alternatives for patients suffering from autoimmune diseases. By focusing on innovative mechanisms and patient-friendly administration routes, Cyxone seeks to address the unmet medical needs in this therapeutic area. Their commitment to research and development is evident in their ongoing projects, which aim to deliver transformative therapies that can significantly enhance patient outcomes.

Sweden

Cyxone AB (publ) is a clinical stage biotech company that develops new innovative therapies for the treatment of rheumatoid arthritis and multiple sclerosis. The company's goal is to improve the quality of life for patients with autoimmune and autoinflammatory diseases.

Cyxone

Company Details